KCTD16 and small cell lung carcinoma: We then confirmed KCTD16-abs as a strong biomarker of an underlying SCLC, as previously described3; KCTD16-abs should therefore be requested in all cases of GABABR-AE without a known tumor, and their presence should warrant thorough and repeated tumor screening.